3D lung organoid platform for preclinical testing of drugs targeting senescence
2024
Saarland University, Homburg, Germany
Chronic lung diseases such as chronic obstructive pulmonary disease and cystic fibrosis are incurable. Epithelial senescence, a state of dysfunctional cell cycle arrest, contributes to the progression of such diseases. Therefore, lung epithelial cells are a valuable target for therapeutic intervention. Here, a 3D airway lung organoid platform for the preclinical testing of active substances is presented with regard to senescence, toxicity, and inflammation under standardized conditions in a 96 well format. Senescence was induced with doxorubicin and measured by activity of senescence associated galactosidase. Pharmaceutical compounds such as quercetin antagonized doxorubicin-induced senescence without compromising organoid integrity. Using single cell sequencing, a subset of cells expressing senescence markers which was decreased by quercetin was identified. Doxorubicin induced the expression of detoxification factors specifically in goblet cells independent of quercetin. In conclusion, the platform enables the analysis of senescence-related processes and will allow the pre-selection of a wide range of compounds (e.g. natural products) in preclinical studies.
Biochemical and transcriptomic evaluation of a 3D lung organoid platform for pre-clinical testing of active substances targeting senescence
Christoph Beisswenger
Added on: 02-16-2024
[1] https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-023-02636-7?emci=d9d8e003-77b1-ee11-bea1-0022482237da&emdi=949961fe-95b1-ee11-bea1-0022482237da&ceid=2015591
